
Eli Lilly, UCB and others Switch into gear with $52M for new RNA biotech
South San Francisco biotech Switch Therapeutics unwrapped Tuesday morning with $52 million to finance conditionally activated siRNA molecules.
As its name suggests, the startup said it can switch on the molecules only in selected cells so they’re more precise than other RNAi approaches and can potentially be effective for longer periods. The biotech will start in the central nervous system and consider expanding its use in other disease areas through the help of potential pharma collaborators, CEO Dee Datta told Endpoints News.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.